Hot Flashes Treatment

What Is Actually Happening During a Hot Flash

A hot flash is a thermoregulatory event. The hypothalamus contains a small population of neurons — often called KNDy neurons, for the kisspeptin, neurokinin B and dynorphin they produce — that help set the body's internal temperature range. Estrogen normally restrains these neurons. As ovarian estrogen production falls during the menopause transition, they become more active and the range of temperatures your body tolerates without reacting narrows sharply. A small rise in core temperature that you would not have noticed at 40 now triggers the full heat-dissipation response: skin vessels dilate, you flush, you sweat, and then you feel chilled as the sweat evaporates.

This mechanism is why hot flashes cluster at night and fragment sleep, and it explains why the newest drugs for hot flashes target neurokinin receptors directly rather than replacing estrogen. It also explains why hot flashes are not purely a hormone-level problem: blood estrogen levels correlate poorly with symptom severity, which is one reason we do not treat a lab value in isolation.

Not every hot flash is menopausal. Thyroid disease, certain medications, carcinoid syndrome, infection, anxiety disorders and alcohol use can all produce flushing or night sweats. Part of a proper evaluation is ruling these out before committing to a treatment.

Hormone Therapy and What "Bioidentical" Really Means

Estrogen therapy remains the most effective treatment for moderate to severe vasomotor symptoms, and The Menopause Society has consistently taken that position. In November 2025 the FDA announced the removal of the boxed warning from hormone therapy products containing estrogen, with revised, age-specific labeling reflecting evidence that the risk profile is more favorable for women who begin therapy before about age 60 or within roughly ten years of their final period. The boxed warning regarding endometrial cancer remains on systemic estrogen-only products, which is why women with a uterus are also prescribed a progestogen.

Removing a warning is not the same as removing risk. Hormone therapy is still not appropriate for everyone — a personal history of breast cancer, estrogen-dependent cancer, unexplained vaginal bleeding, active liver disease, or prior venous thromboembolism or stroke are among the reasons a physician may steer you elsewhere. Route matters too, and transdermal versus oral delivery is a real part of the conversation.

The word "bioidentical" causes a great deal of confusion, so we want to be precise about it. Bioidentical simply means the hormone is structurally identical to what the body makes. Several bioidentical hormones are FDA-approved, manufactured products — estradiol in pills, patches and gels, micronized progesterone, and the combined estradiol-progesterone capsule Bijuva. Custom-compounded bioidentical preparations are a different matter: the 2020 National Academies of Sciences, Engineering, and Medicine report commissioned by the FDA found the evidence for compounded bioidentical hormone therapy to be of low quality and raised public health concerns about its widespread use. Where an FDA-approved bioidentical product will do the job, our physicians prefer it.

Non-Hormonal Prescription Options

For women who cannot take estrogen or would rather not, there are now several prescription options, and this category has changed more than any other in recent years.

Fezolinetant, sold as Veozah, was approved by the FDA in 2023 for moderate to severe vasomotor symptoms due to menopause. It is a neurokinin-3 receptor antagonist — it works on the hypothalamic pathway described above rather than by supplying hormone. We want to be plain about its safety profile: in December 2024 the FDA added a boxed warning for rare but serious liver injury, along with a schedule of liver function testing before and during treatment. Anyone we prescribe it to is counseled on the warning signs and follows that monitoring schedule.

Elinzanetant, sold as Lynkuet, was approved by the FDA in October 2025. It blocks both neurokinin-1 and neurokinin-3 receptors. In the OASIS-3 trial, women taking elinzanetant had a substantially greater reduction in moderate-to-severe hot flash frequency at twelve weeks than women taking placebo, with reported improvements in sleep quality as well — though the placebo response in these trials is itself large, and a trial average is not a prediction of what any individual woman will experience.

Older options remain useful and are often less expensive. Low-dose paroxetine mesylate at 7.5 mg, marketed as Brisdelle, is the only SSRI with FDA approval specifically for vasomotor symptoms; it is generally avoided in women taking tamoxifen. Other SSRIs and SNRIs, gabapentin and oxybutynin are used off-label, and the 2023 nonhormone therapy position statement of The North American Menopause Society lists SSRIs/SNRIs, gabapentin and fezolinetant among its recommended therapies.

Non-Drug Approaches: What Holds Up and What Doesn't

Two behavioral therapies have genuine evidence behind them. The Menopause Society's 2023 nonhormone position statement recommends cognitive behavioral therapy and clinical hypnosis for bothersome vasomotor symptoms, both supported by its highest evidence level. These do not appear to reduce the physiological flush as much as they reduce how disruptive and distressing it feels — which, for many women, is the outcome that matters. They are also compatible with every medication listed above.

Practical measures are worth trying alongside anything else: layered clothing, a cooler bedroom, limiting alcohol and identifying your own triggers, and treating any untreated sleep problem on its own terms. Smoking cessation and weight management are both associated with better symptom burden.

We would rather be honest than agreeable about supplements. The same 2023 position statement does not recommend herbal and dietary supplements for hot flashes, including black cohosh and soy-derived products, on the grounds that the evidence does not demonstrate benefit. Some are marketed aggressively, and some can interact with prescription medications or affect the liver. If you are taking one, bring the bottle to your appointment so we can review it.

Who Is a Candidate, and What Your First Visit Looks Like

You may be a candidate for treatment if hot flashes or night sweats are frequent enough to interfere with your sleep, work, concentration or quality of life — including during perimenopause, while you are still having periods. Women with surgical or treatment-induced menopause often have abrupt, severe symptoms and should not wait. Breast cancer survivors and women with a history of blood clots, stroke, liver disease or unexplained bleeding can still be treated; the path is simply a non-hormonal one, and we coordinate with your oncologist where relevant.

Your first visit at our Buckhead office is a consultation, not a sales appointment. Expect a detailed symptom history — frequency, severity, night waking, how long this has been going on — along with your full medical, surgical, medication and family history, a review of cardiovascular and breast cancer risk, and confirmation that your screening is current. We typically order baseline laboratory work, which may include thyroid function, a metabolic panel including liver enzymes, a lipid panel, and hormone levels where they will change the plan.

You and your physician then decide together whether to start with hormone therapy, a non-hormonal prescription, a behavioral approach, or a combination — and what you are willing to accept in the way of monitoring and cost. Eligibility and dosing are always determined by the physician after this evaluation, and we will tell you directly if we think the honest answer is that no medication is warranted yet.

Monitoring, Follow-Up, and How This Fits with Your Other Care

Starting treatment is the beginning of the process, not the end of it. Most patients are seen again within roughly six to twelve weeks to review whether symptoms have improved, whether side effects have appeared, and whether the approach should be adjusted. Certain medications carry their own required monitoring — fezolinetant's FDA label, for example, specifies liver function testing at baseline and at set intervals during the first months of treatment. Women on hormone therapy have their risk-benefit balance revisited periodically rather than staying on an unexamined prescription indefinitely, and we keep your gynecologist and primary care physician in the loop.

Hot flashes rarely arrive alone. If yours come with sleep disruption, mood changes, vaginal dryness, joint aches, brain fog or weight gain, those belong in the same conversation. Related pages you may find useful: /services/menopause-treatment for the broader transition, /services/hormone-replacement-therapy and /services/bioidentical-hormone-replacement-therapy for the hormonal options in more depth, /services/anti-aging-treatments for our longevity and preventive work, and /services/weight-loss-atlanta-ga if midlife weight change is part of the picture.

Atlanta Medical Institute has practiced from a single office at 5009 Roswell Road NE, Suite 201, in Buckhead since 2010. Dr. Elbridge Bills, Dr. Jeff Semel and Dr. Leslye Pace see patients Monday through Thursday from 9 to 6 and Friday from 9 to 4. You can read more about them at /about/dr-elbridge-bills, /about/dr-jeff-semel and /about/dr-leslye-pace, or call (404) 264-9553 to schedule an evaluation.